Table 4.
Aspergillus onychomycosis reported in some countries.
| Authors | Country | Species | Treatment | Context |
|---|---|---|---|---|
| Merad et al. 2020 [31] | Algeria | A. flavus | Oral terbinafin 250 mg/day + amorolfine 5% nail lacquer. | No underlying disease |
| Hirose et al. 2018 [104] | Japan | A. subramanianii | Terbinafine resolution after 6 month | No underlying disease |
| Moubasher et al. 2017 [105] | Egypt |
A. niger, A. flavus,
A. terreus |
- | No underlying disease |
| Motamedi et al. 2016 [106] | Iran | A. flavus | - | - |
| Sharma et al. 2015 [107] | India | A. tetrazonus | - | - |
| Zotti et al. 2015 [108] | Italy | A. melleus | - | - |
| Wijesuriya et al. 2015 [64] | Sri Lanka | A. niger (76%) | - | Diabetic population |
| Nouripour-Sisakht et al. 2015 [109] | Iran | Aspergillus sp: 87.8% (135/463) | - | - |
| Ahmadi et al. 2012 [110] | Iran | A. candidus | Oral itraconazole 10 weeks (resistance to terbinafine) | No underlying disease |
| Zotti et al. 2010 [111] | Italy | A. persii | In vitro susceptibility to itraconazole | No underlying disease |
| Choudhary et al. 2009 [52] | India | A. flavus | - | HIV patient (Proximal onyxis) |
| Brasch et al. 2009 [112] | Germany | A. ochraceopetaliformis | Oral Terbinafine+ ciclopiroxolamine |
No underlying disease |